'Camzyos,' a new drug to treat obstructive hypertrophic cardiomyopathy (oHCM), will finally be listed for reimbursement.

The Ministry of Health and Welfare (MOHW) held the 23rd Health Insurance Policy Review Committee meeting on November 28, announcing that BMS Korea’s Camzyos (mavacamten), a new drug used to treat obstructive hypertrophic cardiomyopathy (oHCM) will be reimbursed.

As a result, prescriptions for Camzyos are expected to increase starting in next year (December).

Camzyos, which was approved in May 2023, received a re-assessment status during the Drug Reimbursement Evaluation Committee (DREC) review of the Health Insurance Review and Assessment Service (HIRA)